Main Story
-
New global IKEA study: Nearly 4 in 10 are staging a “silent protest” over household mess
MALMÖ, Sweden, Aug. 24, 2026 /PRNewswire/ — In 38% of homes, someone is quietly leaving things out and hoping someone else will deal with it. (They won’t.) Welcome to the silent protest. It’s one of many findings from the IKEA Store & Organise Report 2026: Finding Meaning in the Mess. Life at home is getting…
Products
-
AccuSure AS9 Fully Automatic Digital Blood Pressure Monitor With Large Display
Original price was: ₹1,733.00.₹998.00Current price is: ₹998.00. -
AGEasy Max Group Fully Automatic One Touch Digital Blood Pressure Monitoring Device
Original price was: ₹1,405.00.₹949.00Current price is: ₹949.00. -
Automatic Digital Blood Pressure Monitor for Upper Arm, Large LCD Display
Original price was: ₹2,399.00.₹448.00Current price is: ₹448.00. -
Beurer German Engineering P0 13 Kid’s Pulse Oximeter I Fingertip Home Pulse Oximeter
Original price was: ₹2,745.00.₹1,538.00Current price is: ₹1,538.00. -
BPL Medical Technologies Bluetooth Enabled Arm Type Blood Pressure Monitor
Original price was: ₹6,563.00.₹5,199.00Current price is: ₹5,199.00.
Automobile
Tech
Entertainment
-
Bisleri Unveils Limited-Edition Packs Featuring Nivin Pauly and Mamitha Baiju from 'Bethlehem Kudumba Unit'
Thiruvananthapuram, Kerala, India Bisleri International, India’s leading packaged drinking water brand, has announced its latest limited-edition pack association with Bethlehem Kudumba Unit, bringing the excitement of one of the most anticipated Malayalam film releases closer to consumers across Kerala. As part of the collaboration, Bisleri will introduce special-edition bottles featuring the film’s lead actors, Nivin…
Health
-
Onco360® Has Been Selected as a National Pharmacy Partner for RASONQUE™ (daraxonrasib)
LOUISVILLE, Ky., Aug. 26, 2026 (GLOBE NEWSWIRE) — Onco360®, the nation’s leading independent Specialty Pharmacy, is grateful to be selected as a pharmacy partner by Revolution Medicines for RASONQUE™ (daraxonrasib), which is an inhibitor of the RAS GTPase family, indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least…
-
Biosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase beta
BUENOS AIRES, Argentina, Aug. 26, 2026 /PRNewswire/ — Biosidus, an Argentine biotechnology company with more than four decades of experience in the development and manufacturing of biosimilar medicines, announced that its new bioreactor plant is now operational, increasing the company’s biologics production capacity and reinforcing its ability to support potential international demand. The expansion strengthens Biosidus’…
-
Celularity Provides Update Regarding Nasdaq Listing Compliance
FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period…
-
Metabolon Completes Landmark Global Health Pilot Advancing Women’s and Infant Health
Innovative sample collection methods developed through Gates Foundation-funded grant enable high-quality metabolomics biomarker discovery in populations from low- and middle-income countries MORRISVILLE, N.C., Aug. 25, 2026 /PRNewswire/ — Metabolon, Inc., the global leader in metabolomics solutions advancing life science research, diagnostics, therapeutics, and precision medicine, today announced the successful completion of multiple pilot projects funded…
-
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
NANJING, China, Aug. 24, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), has completed its safety run‑in assessment and advanced to…
-
ICP DAS-BMP Brings Advanced Medical TPU Portfolio to Medical Manufacturing Asia 2026
HSINCHU, Aug. 25, 2026 /PRNewswire/ — ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), will exhibit at Medical Manufacturing Asia 2026, taking place September 9–11 at the Marina Bay Sands Expo & Convention Centre in Singapore (Booth 2U20). Exhibiting together with its manufacturing partner, Towards Buddha Co., Ltd., the…
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
